Drugs / ENITOCICLIB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04978779 | Dec 2021 → May 2023 | B-cell chronic lymphocytic leukemia, Richter transformation, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement | Vincerx Pharma, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02745743 | Jun 2016 → Aug 2018 | hematopoietic and lymphoid cell neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02635672 | Feb 2016 → Nov 2024 | neoplasm | Vincerx Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05371054 | Apr 2023 → Jul 2024 | non-Hodgkin lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENITOCICLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4756595 ↗ |
| Known as | BAY 1251152 | “Investigating VIP152 (BAY 1251152) in a dose escalation cohort in patients with solid tumors and aggressive NHL” NCT02635672 ↗ |
| Known as | VIP152 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04978779 ↗ |
| Action | Inhibit | “a potent and highly selective cyclin-dependent kinase 9 (CDK9) inhibitor” PMID 35046056 ↗ Apr 2022 |
| Modality | Small molecule | — CHEMBL4756595 ↗ |
| Route | Intravenous | “The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion)” NCT02635672 ↗ |
| Target | CDK9 | “Enitociclib, a Selective CDK9 Inhibitor” PMID 37882668 ↗ Nov 2023 |